Cited by 162Epilepsy research and treatmentInflammatory mediators and NSAID effectsNeuroinflammation and Neurodegeneration Mechanisms

Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management

Open access
Rawat, Chitra, Kukal, Samiksha, Dahiya, Ujjwal Ranjan, Kukreti, Ritushree·2019·Journal of Neuroinflammation

Abstract

Epilepsy, a common multifactorial neurological disease, affects about 69 million people worldwide constituting nearly 1% of the world population. Despite decades of extensive research on understanding its underlying mechanism and developing the pharmacological treatment, very little is known about the biological alterations leading to epileptogenesis. Due to this gap, the currently available antiepileptic drug therapy is symptomatic in nature and is ineffective in 30% of the cases. Mounting evidences revealed the pathophysiological role of neuroinflammation in epilepsy which has shifted the focus of epilepsy researchers towards the development of neuroinflammation-targeted therapeutics for epilepsy management. Markedly increased expression of key inflammatory mediators in the brain and blood-brain barrier may affect neuronal function and excitability and thus may increase seizure susceptibility in preclinical and clinical settings. Cyclooxygenase-2 (COX-2), an enzyme synthesizing the proinflammatory mediators, prostaglandins, has widely been reported to be induced during seizures and is considered to be a potential neurotherapeutic target for epilepsy management. However, the efficacy of such therapy involving COX-2 inhibition depends on various factors viz., therapeutic dose, time of administration, treatment duration, and selectivity of COX-2 inhibitors. This article reviews the preclinical and clinical evidences supporting the role of COX-2 in seizure-associated neuroinflammation in epilepsy and the potential clinical use of COX-2 inhibitors as a future strategy for epilepsy treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12974-019-1592-3

Cites

164 of 164 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tolfenamic acid is an inhibitor of the enzyme cyclooxygenase (COX), also called prostaglandin-endoperoxide synthase (PTGS), which is involved in the conversion of fatty acids to prostaglandin and is targeted by a variety of anti-inflammatory drugs.

    “TA is an inhibitor of the enzyme cyclooxygenase (COX), also called prostaglandin-endoperoxide synthase (PTGS), which is involved in the conversion of fatty acids to prostaglandin41 and is targeted by a variety of anti-inflammatory drugs42.”

    From A statistical framework for high-content phenotypic profiling using cellular feature distributions (2022) · cites this paper as [42]

    Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rawat, C., Kukal, S., Dahiya, U. R., & Kukreti, R.
Affiliations
Institute of Genomics and Integrative Biology (IN)
Corresponding author
Kukreti, Ritushree
Venue
Journal of Neuroinflammation
Published
2019-10-30
Volume
16
Issue
1
Pages
197-197
ISSN
1742-2094 (ISSN-L)
OpenAlex
W2982629815
Cited by
162
References
164
Citations by year
2026: 16 · 2025: 24 · 2024: 28 · 2023: 37 · 2022: 17 · 2021: 28 · 2020: 12
FWCI
2.40
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroinflammation (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Greater South Information System
Funders
Council of Scientific and Industrial Research (MLP1804)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Epilepsy research and treatment
  • Health Sciences › Medicine › Pharmacology › Inflammatory mediators and NSAID effects
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
cyclooxygenase-2, COX-2 inhibitors, epilepsy, neuroinflammation, epileptogenesis, seizures, prostaglandins, blood-brain barrier, antiepileptic drugs, seizure susceptibility
MeSH terms
Animals, Anticonvulsants, Clinical Trials as Topic, Epilepsy, Forecasting, Humans, Disease Management, Cyclooxygenase 2 Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review